Exicure, Inc.

NasdaqCM:XCUR

Sector

🏥 Health Care

Industries

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 55.41 M

Share Price

USD 8.77

Avg Daily Volume

20,585

Change (1 day)

-2.45%

Change (1 year)

422.02%

Change (YTD)

-35.84%

Exicure, Inc. Price to Book Ratio (P/B) on June 13, 2025

Exicure, Inc. Price to Book Ratio (P/B) is NA on June 13, 2025. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Exicure, Inc. 52-week low Price to Book Ratio (P/B) is NA on June 13, 2025, which is NA below the current Price to Book Ratio (P/B).
Exicure, Inc. 52-week low Price to Book Ratio (P/B) is NA on June 13, 2025, which is NA below the current Price to Book Ratio (P/B).
Exicure, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Daily

From:

To:

Zoom:

Key data

Date	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield

NasdaqCM: XCUR

Exicure, Inc.

CEO	Mr. Andy Yoo
IPO Date	May 22, 2018
Location	United States
Headquarters	2430 North Halsted Street
Employees	7
Sector	🏥 Health Care
Industries Biotechnology 💊 Pharmaceuticals

Description

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.